Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 12/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463217 | 0.87 | GRIK1 (1.00) | GRIK1MAPTRXFP1MEN1KMT2A | |
| SCHEMBL22567938 | 0.83 | MAPT (0.78) | ALDH1A1MAPTGAANPSR1TDP1 | |
| SCHEMBL22223417 | 0.83 | GRIK1 (0.66) | GRIK1ALDH1A1MAPTGAANPSR1 | |
| Flufenamic Acid SCHEMBL29356958 | 0.82 | RXFP1 (0.75) | GRIK1ALDH1A1TDP1RXFP1MEN1 | |
| Flufenamic Acid SCHEMBL17497 | 0.82 | RXFP1 (0.75) | GRIK1ALDH1A1TDP1RXFP1MEN1 | |
| SCHEMBL5455412 | 0.82 | CA1 (0.71) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL31212658 | 0.82 | CA1 (0.71) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL7175227 | 0.82 | MAPT (0.86) | ALDH1A1MAPTGAANPSR1TDP1 | |
| SCHEMBL16322745 | 0.81 | ALDH1A1 (0.70) | ALDH1A1MAPTGAANPSR1TDP1 | |
| Flufenamic Acid SCHEMBL11524554 | 0.81 | RXFP1 (0.73) | GRIK1ALDH1A1TDP1RXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | GRIK1 655/4885ALDH1A1 327/4885MAPT 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.